Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Ocumetics Technology Corp OTCFF


Primary Symbol: V.OTC

Ocumetics Technology Corp. is a Canada-based research and product development company. The Company specializes in adaptive lens designs. It is in the preclinical study stage of development of an intraocular lens. It is focused on developing intraocular lenses for people over 45 years of age. The Ocumetics lens, which is an expandable intraocular lens that fits within the natural lens compartment of the eye to eliminate the need for corrective lenses. It is designed to allow the eye’s natural muscle activity to shift focus from distance to nearby. The Lens consists of self-adapting suspension systems that modulate curvature change. The Lens’s suspension systems are comprised of cushions that are designed to conform to unique parameters of each recipient’s eye. When ciliary muscles relax, during sleep or when the eye focuses upon distant objects, the optical interface is compressed into its high energy state by expansion of the suspension system.


TSXV:OTC - Post by User

Post by stocksavvy2000on Nov 22, 2024 5:26pm
28 Views
Post# 36326884

Enhances Intraocular Lens Design Ahead of Human Trials

Enhances Intraocular Lens Design Ahead of Human Trialsrefines AIOL design for improved safety and performance, delaying FIH trials by 45-60 days to meet rigorous quality standards
<< Previous
Bullboard Posts